1366′s Sunny Start, Adimab’s Second Round, Constant Contact’s Second Offering, and More Deals News

3/31/08

Another somewhat sluggish week, deals-wise. Perhaps everybody was too busy trying to uncover the identities of the members of the MIT blackjack team?

—Biotech startup Adimab of Lebanon, NH, closed a Series B financing round co-led by Polaris Venture Partners and SV Life Sciences. The total raised in the deal, which comes less than a year after the company closed a $6.2 million Series A round led by the same venture firms, was not disclosed.

—Metatomix of Dedham, MA, announced a partnership with IBM. Big Blue will help market the Massachusetts firm’s semantic Web technology for public safety applications. Wade explained how it all works in a profile of Metatomix.

—Highland Capital Partners VII and the Highland Consumer Fund participated in a $20 million growth capital investment in Pharmaca Integrative Pharmacy of Boulder, CO.

—1366 Technologies, a brand-new MIT solar energy spinoff based in Lexington, MA, raised $12.4 million in a Series A round led by North Bridge Venture Partners and Polaris Venture Partners. The funding will support 1366′s efforts to make solar power cost-competitive with coal.

—E-mail marketing firm Constant Contact of Waltham, MA, filed for a 4.4 million share secondary offering; the lion’s share of the shares are to be offered by venture firms and other Constant Contact shareholders.

By posting a comment, you agree to our terms and conditions.